Benicar Legal News Articles & Interviews

Santa Cruz, CA: Prospective plaintiffs who did not make it into the $300 million Benicar settlement and concerned about the capacity for filing a Benicar lawsuit going forward will be cheered by the latest petition to the US Food and Drug Administration (FDA) by the consumer advocacy group Public Citizen.

Camden, NJ: Daiichi Sankyo’s recent $300 million Benicar lawsuit settlement will end the story for some who were hurt by the blood pressure drug. But it will leave others out in the cold.

New York, NY: It appears as if the recent announcement that Benicar manufacturer Daiichi Sankyo will make available $300 million to settle claims over Benicar side effects will not prove to be a hardship for the Japanese drug maker. The Reuters news agency (08/01/17) reported last month that according to a statement from Daiichi Sankyo, the settlement is expected to be funded by a collective of insurance companies underwriting Daiichi’s liabilities. As such, Daiichi Sankyo said the settlement would not have a material impact on its financial position.

Santa Cruz, CA:Drug maker Daiichi Sankyo has now offered $300 million to settle more than 2,000 Benicar lawsuits based on allegations that blood pressure medications, Benicar, Benicar HCT, Azor, and Tribenzor caused serious gastrointestinal injuries. But Mylan Pharmaceuticals Inc., Apotex, Inc., Lupin Pharmaceuticals Inc. and Ascend Laboratories LLC are in various stages of marketing generic Benicar in the US. A Canadian version of Daichi Sankyo’s Benicar, sold under the name Olmetec, is also available to Americans who manage to do their prescription shopping over the border. Cost-conscious consumers may miss out on information about Benicar side effects when they buy essentially the same drug under another name.

Houston, TX Users of the blood pressure medication Benicar will receive an estimated average payout of $100,000 each in a settlement deal reached with Diiachi Sankyo and Forest Laboratories. The company admits no liability but agreed to pay compensation plaintiffs to some individuals who experienced gastrointestinal problems after using the medication.

Camden, NJ: When the manufacturers and marketers of Benicar agreed to the $300 million settlement to resolve state and federal Benicar lawsuits, they did so while admitting no liability for any wrongdoing, and maintaining their position that claims have no merit.

Trenton, NJ: A Benicar lawsuit alleging Benicar side effects has been disentangled from one if its defendants after a doctor was summarily dismissed from the lawsuit on grounds that his inclusion in the lawsuit was without merit.

Camden, NJ: This spring has seen some developments in the Benicar side effects multidistrict litigation over gastrointestinal issues and sprue-like enteropathy associated with olmesartan (Benicar), a medication prescribed for high blood pressure. By the middle of March there were some 1,800 Benicar cases housed in the Benicar MDL in New Jersey.

Parsippany, NJ: This could evolve to a compelling year for Japanese-based pharmaceutical giant Daiichi Sankyo following the expiry of its patent exclusivity for Benicar last year and a corresponding drop in revenue for a product characterized as its global mainstay. As generics for olmesartan (Benicar) continue to gain market share in 2017, coupled with a growing number of Benicar lawsuits which number around 1,700 and climbing, industry watchers will be monitoring Daiichi in the coming months and years to see how the corporation responds, and what effect that may have on consumers.